Tag
Chemkart India Limited
5 articles
Chemkart India demonstrates robust financial performance and disciplined capital allocation, signaling positive momentum for investors. The company reported INR 21,482.91 crore in revenue for FY26, alongside a net profit of INR 2,077.2 crore and a healthy cash position of INR 3,864.5 crore, despite global supply chain headwinds. Furthermore, Chemkart confirmed full utilization of its IPO proceeds as outlined in the prospectus, with investments in manufacturing and debt repayment, and highlighted a strong order pipeline exceeding INR 6,526 crore, suggesting continued growth potential within the expanding nutraceutical market. Insider buying activity from promoters and directors further reinforces confidence in the company's future prospects.
Chemkart India H2-FY26 Investor Presentation Highlights
Chemkart India reported FY26 consolidated revenue of INR 21,482.91 lakhs with 7.1% volume growth despite global supply chain challenges.
The company is constructing a greenfield nutraceutical CDMO fac
Chemkart India Reports No IPO Fund Deviation
Chemkart India Limited filed a regulatory statement confirming no deviation in IPO fund utilization for H1 FY26.
The company raised ₹64.48 crore through IPO with net proceeds of ₹54.68 crore allocated
Chemkart India FY26 Net Profit ₹20.78 Crore
Chemkart India approved audited standalone and consolidated financial results for H2 and full year ended March 31, 2026, reporting ₹21,259.48 lakh revenue and ₹2,077.22 lakh net profit.
The Board appo
Chemkart India Promoter Acquires 4,200 Equity Shares
Chemkart India Limited (BSE: 544442) discloses insider trading form under SEBI PIT Regulations 2015.
Promoter-Director Shailesh Vinodrai Mehta acquired 4,200 equity shares worth ₹4,07,676 on 25 March
Chemkart India Director Acquires 10,800 Equity Shares
Chemkart India Limited (BSE: 544442) filed an insider trading disclosure under SEBI PIT Regulations 2015 on 26 March 2026.
Director Ankit Shailesh Mehta (DIN: 06792217) acquired 10,800 equity shares,